BioCryst Pharmaceuticals
BCRX
BCRX
103 hedge funds and large institutions have $425M invested in BioCryst Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 35 increasing their positions, 33 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
11% less funds holding
Funds holding: 116 → 103 (-13)
55% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 22
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Holders
103
Holding in Top 10
1
Calls
$895K
Puts
$438K
Top Buyers
| 1 | +$13M | |
| 2 | +$6.17M | |
| 3 | +$4.37M | |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.91M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$2.67M |
Top Sellers
| 1 | -$16.6M | |
| 2 | -$4.86M | |
| 3 | -$4.58M | |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.42M |
| 5 |
AG
Artal Group
Luxembourg
|
-$2.46M |